Q2 25 EPS
$2.01
BEAT +2.72%
Est. $1.96
Q2 25 Revenue
$7.08B
BEAT +1.69%
Est. $6.96B
vs S&P Since Q2 25
-3.9%
TRAILING MARKET
GILD +11.2% vs S&P +15.1%
Market Reaction
Did GILD Beat Earnings? Q2 2025 Results
Gilead Sciences posted a clean beat across the board in Q2 2025, reporting non-GAAP diluted EPS of $2.01 against a consensus estimate of $1.96, a 2.72% positive surprise, while revenue climbed 1.9% year-over-year to $7.08 billion, clearing the $6.96 … Read more Gilead Sciences posted a clean beat across the board in Q2 2025, reporting non-GAAP diluted EPS of $2.01 against a consensus estimate of $1.96, a 2.72% positive surprise, while revenue climbed 1.9% year-over-year to $7.08 billion, clearing the $6.96 billion estimate by 1.69%. The headline driver behind the quarter's strength was HIV, which generated $5.09 billion in sales, up 7% year-over-year, with Biktarvy alone contributing $3.53 billion and Descovy surging 35% to $653 million on favorable pricing and volume. That momentum was partially offset by a steep 44% drop in Veklury to $121 million as COVID-19 hospitalizations declined, a dynamic that also prompted Gilead to trim its full-year Veklury outlook to $1.0 billion. Even so, management raised its full-year non-GAAP EPS guidance to $7.95–$8.25 and lifted product sales guidance to $28.3–$28.7 billion, reflecting confidence in the core franchise. Shares jumped roughly 8.8% following the report, as investors also cheered the FDA approval of Yeztugo, the first twice-yearly HIV prevention option, as a potentially transformative milestone for Gilead's virology business.
Key Takeaways
- • Biktarvy demand growth driving 9% YoY sales increase to $3.5 billion
- • Descovy sales surging 35% YoY on higher average realized price and demand
- • HIV portfolio overall up 7% YoY on increased demand and higher average realized price
- • Trodelvy sales up 14% YoY on higher demand and inventory dynamics
- • Growing demand for Livdelzi and Hepcludex within Liver Disease portfolio
- • Product mix improvement driving non-GAAP product gross margin expansion to 86.9%
GILD YoY Financials
Q2 2025 vs Q2 2024, source: SEC Filings
GILD Revenue by Segment
With YoY comparisons, source: SEC Filings
GILD Revenue by Geography
With YoY comparisons, source: SEC Filings
“This was a very successful second quarter for Gilead, including the FDA approval for Yeztugo as the world's first twice-yearly HIV prevention option. Our strong growth this quarter was driven by Biktarvy, Descovy, Trodelvy and Livdelzi, reflecting the diversity of our portfolio. As we enter the third quarter, we are increasing revenue and earnings guidance for the year, and look forward to delivering continued innovation and growth across our core therapeutic areas.”
— Daniel O'Day, Q2 2025 Earnings Press Release
GILD Earnings Trends
GILD vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
GILD EPS Trend
Earnings per share: estimate vs actual
GILD Revenue Trend
Quarterly revenue: estimate vs actual
GILD Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $1.91 | $2.03 | +6.30% | $6.96B | +0.51% |
| Q4 25 BEAT FY | $1.83 | $1.86 | +1.88% | $7.93B | +3.21% |
| FY Full Year | $8.12 | $8.15 | +0.40% | $29.44B | +0.82% |
| Q3 25 BEAT | $2.14 | $2.47 | +15.67% | $7.77B | +4.14% |
| Q2 25 BEAT | $1.96 | $2.01 | +2.72% | $7.08B | +1.69% |
| Q1 25 BEAT | $1.77 | $1.81 | +2.11% | $6.67B | -2.14% |